The IG for On Football off to a strong start. Thierry Henry runs the division and he got Roger Federer (owns 3% of On Running) talking about beating Henry with his left hand in tennis and breaking out decent juggling moves.

Kylian Mbappé left Nike after ~20 years with the brand and joined On Running. Mbappé reportedly turned down a 10-year $200m deal from Nike. He’ll get On equity and launch its football category (overseen by Thierry Henry). He was spotted wearing On’s wild spray-on shoe technology (LightSpray), a process inspired by glue guns that greatly reduces shoe making time with max customization fit potential: ▫️It takes 3 minutes to finish the upper part of the shoe (see video of running shoe sample) vs. 3 hours with stitching ▫️A single person can operate the machine vs. 100 people on a normal shoe assembly line (and only has 7 parts vs. ~150 to 200) ▫️LightSpray using parametric design principles, and computational engineering (instead of traditional pattern makers). How? Per NYT, a robot arm sprays “a single semi-translucent synthetic monofilament almost a mile long” on to a shoe mold to finish the upper (which is then “heat-fused to a foam rubber and carbon fibre sole”). Hellen Obiri won the 2024 Boston Marathon and 2025 New York Marathon while she wore a version of the LightSpray shoes. Very interested how these shoes perform on soccer pitch. *** The Athletic on Mbappe: NYT on LightSpray:

The section from Citrini’s 2028 Memo on how consumer AI agents will help users navigate the economy’s “rent-extraction layer” worth a re-read: “It started out simple enough. Agents removed friction. Subscriptions and memberships that passively renewed despite months of disuse. Introductory pricing that sneakily doubled after the trial period. Each one was rebranded as a hostage situation that agents could negotiate. The average customer lifetime value, the metric the entire subscription economy was built on, distinctly declined.”

Without the right VBC playbook for 2027... Miss the documentation, fail the audit. Miss the care gap, lose the quality score. Miss both, and you're losing money on the contract. On 9/30, I'm talking with Dana Brandenstein, VP of Provider Enablement at @PriviaHealth, and Dana McCalley, VP of Value-Based Care at @Navina_ai, about what separates the teams that are ready for 2027 from the teams that aren't. We'll discuss: • Why retrospective workflows and delayed follow-up put revenue and audit readiness at risk. • What audit-ready documentation looks like under V28 • How leading organizations stop work from getting lost between teams and tools • Where AI can give your team back time for patients, not paperwork We'll also run through a self-assessment so you can see where your org lands. Join us live or RSVP for the recording.

Amazon has now blocked ChatGPT and Meta Muse from crawling its platform. It clearly wants shoppers to use Amazon’s next-gen AI shopping tools including the “Alexa For Shopping” agent and that random tool that create AI-generated product review podcasts.

Lisa Su with a generational run: ▫️at 44 years old, promoted from AMD COO to CEO in October 2014 ▫️market cap since up >300x from ~$3b to $1T ▫️revenue up ~10x from $5b in 2014 to projected $51b in 2026 ▫️since 2020, grew AMD’s market share of data centre CPUs from 0% to 40%+

2026 really is the year of the health consumer, starting with all aspects of primary care. Off the top of my head, look at what has happened in the first 9 months of 2026 alone: Anyone can order advanced lab testing from their phone. Apple announced it at a $119 price point, alongside more accurate heart monitoring and bifurcated HRV. They also cloned most of WHOOP's feature interface in the process, which leaves form factor as one of the last real differences between the two. Whoop is still very much a core player here, and just raised dang near $600M at a $10B valuation. Fitbit (now part of Google) Air is coming at the category from underneath with Google behind it and no subscription attached to the hardware. ŌURA is going public at a reported $17B+ valuation on over a billy in revenue, with material moves into traditional healthcare settings. DTC telehealth isn't slowing down one bit, between the grifters and the pill mills now selling peptides and compounded GLP-1s next to the labs and the ED meds. Amazon's One Medical announced a slew of AI-enabled offerings, and remains a major pharmacy and primary care provider. And we'll keep seeing new entrants blending direct primary care, longevity (Function Health), and concierge care — all AI-enabled, all offering countless peptides, tests, and technology alongside actual physicians. Which begs the question of which DTC and general consumer players have staying power versus which ones churn out once the novelty (and the funding) wears off. What I'm wondering is...what is the evolving role of primary care when you can order labs through your iPhone, Whoop, or Oura app and then self-assess through AI before anyone in a white coat ever sees the results? I'd welcome thoughts around where you guys see the space evolving, particularly traditional primary care in the midst of all this chaos. It's a brave new world. @Apple @ouraring @onemedical @Google @function @WHOOP

AMD’s market cap has now risen 100x from $10 billion to $1 Trillion since Sky Sports asked Lisa Su if she could “speak English” at the starting grid during 2018 F1 Chinese Grand Prix.